Zevra Therapeutics (NASDAQ:ZVRA) Given New $20.00 Price Target at HC Wainwright

Zevra Therapeutics (NASDAQ:ZVRA) had its price objective hoisted by HC Wainwright from $18.00 to $20.00 in a report published on Friday, Benzinga reports. They currently have a buy rating on the stock.

A number of other research analysts have also commented on the company. William Blair raised Zevra Therapeutics to a strong-buy rating in a research report on Friday, August 30th. Cantor Fitzgerald restated an overweight rating on shares of Zevra Therapeutics in a research report on Wednesday, August 14th. Finally, Canaccord Genuity Group cut their price objective on shares of Zevra Therapeutics from $24.00 to $22.00 and set a buy rating for the company in a research report on Wednesday, September 18th. Five investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of Buy and an average price target of $21.25.

Zevra Therapeutics Stock Performance

Shares of Zevra Therapeutics stock opened at $7.58 on Friday. The stock has a market cap of $317.25 million, a PE ratio of -5.61 and a beta of 1.94. Zevra Therapeutics has a 12 month low of $3.89 and a 12 month high of $8.95. The company has a quick ratio of 2.00, a current ratio of 2.00 and a debt-to-equity ratio of 1.80. The business has a fifty day simple moving average of $7.07 and a 200-day simple moving average of $5.72.

Zevra Therapeutics (NASDAQ:ZVRA) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.47) by ($0.01). The firm had revenue of $4.45 million for the quarter, compared to analysts’ expectations of $4.08 million. Zevra Therapeutics had a negative return on equity of 124.85% and a negative net margin of 274.10%. During the same quarter in the prior year, the business posted ($0.15) earnings per share. On average, sell-side analysts anticipate that Zevra Therapeutics will post -1.58 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, Director John B. Bode purchased 10,000 shares of the business’s stock in a transaction dated Friday, July 12th. The shares were bought at an average cost of $5.87 per share, for a total transaction of $58,700.00. Following the completion of the acquisition, the director now directly owns 30,000 shares in the company, valued at approximately $176,100. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. In the last three months, insiders have purchased 22,000 shares of company stock worth $140,340. Company insiders own 2.40% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ZVRA. Price T Rowe Associates Inc. MD acquired a new position in shares of Zevra Therapeutics in the first quarter valued at approximately $64,000. The Manufacturers Life Insurance Company grew its holdings in Zevra Therapeutics by 15.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,573 shares of the company’s stock valued at $91,000 after buying an additional 2,452 shares in the last quarter. Focus Financial Network Inc. ADV bought a new position in Zevra Therapeutics during the 4th quarter worth $141,000. Virtu Financial LLC acquired a new stake in shares of Zevra Therapeutics during the fourth quarter worth $177,000. Finally, Jacobs Levy Equity Management Inc. lifted its holdings in shares of Zevra Therapeutics by 102.4% during the first quarter. Jacobs Levy Equity Management Inc. now owns 34,707 shares of the company’s stock worth $201,000 after buying an additional 17,557 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.